You just read:

Janssen Presents New Four-Year TREMFYA® (guselkumab) Data Demonstrating Maintained Rates of Skin Clearance in Adult Patients with Moderate to Severe Plaque Psoriasis

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 17, 2019, 16:01 ET